Cetrelimab
- Generic Name
- Cetrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050478-92-5
- Unique Ingredient Identifier
- LYK98WP91F
- Background
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
- Associated Conditions
- -
- Associated Therapies
- -
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04592237
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 22
- Registration Number
- NCT03547037
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵National Cancer Center Hospital, Chuo-Ku, Japan
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 125
- Registration Number
- NCT03473743
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸Toledo Clinic Cancer Centers, Toledo, Ohio, United States
🇺🇸Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT03357952
- Locations
- 🇧🇪
Algemeen Ziekenhuis Klina, Brasschaat, Belgium
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇧🇪UZBrussel, Brussel, Belgium
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 413
- Registration Number
- NCT02908906
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.